▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #988 by analyst upside · 2026-09-29
CADL
Candel Therapeutics, Inc.
Healthcare · Market Cap $856M · P/E 0x
ANALYST PRICE TARGET
+94.4%
implied upside to consensus target
Current Price $11.19
Consensus Target $21.75
Bull Target $29.0
Bear Target $15.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
8
Hold
0
Sell
0
52-Week Low $4.35
52-Week High $14.0
YTD Return +105.7%
FUNDAMENTALS
Market Cap $856M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.49
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $4.35
52-Week High $14.0
Current Price $11.19
Bear Target $15.0
Bull Target $29.0
● Now $11.19 ● Target $21.75
TRADING DATA
Avg Volume 1.3M
YTD Return +105.7%
Analyst Count 8
Consensus Buy
Upside to Target +94.4%
Last Updated 2026-09-29

ANALYST SUMMARY

Candel Therapeutics, Inc. (CADL) is currently trading at $11.19 with a Wall Street consensus price target of $21.75, implying potential upside of 94.4% over the next 12 months. 8 analysts currently cover CADL, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $29.0, while the most cautious has a target of $15.0.

CADL operates in the Healthcare sector with a market capitalisation of $856M. The stock is up 105.7% year-to-date and is currently trading near the upper end of its 52-week range of $4.35 – $14.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CADL, with each firm's 90-day track record across all stocks we track. See full firm rankings →

B of A Securities ↑ Upgrade
Neutral → Buy 2026-09-21 Building track record
B of A Securities - Reiterated
Neutral → Neutral 2026-08-14 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-08-13 31% win rate (48 calls)
Stifel ● Initiated
Buy 2026-07-13 Building track record
Cantor Fitzgerald ● Initiated
Overweight 2026-04-20 40% win rate (10 calls)
Citigroup - Reiterated
Buy → Buy 2026-03-18 Building track record
Citigroup - Reiterated
Buy → Buy 2026-03-13 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-03-13 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
49
out of 100
Coverage depth
17/30
Consensus clarity
5/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →